Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$480.26
+0.7%
$508.75
$425.00
$616.00
$172.16B1.592.17 million shs1.44 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$176.76
+1.2%
$161.28
$140.68
$177.27
$425.70B0.418.41 million shs9.48 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$28.02
+5.0%
$29.20
$23.15
$91.99
$10.90B1.838.65 million shs9.36 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.58
+1.6%
$7.15
$5.01
$15.22
$1.56B2.58.00 million shs7.19 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.00%+2.17%-7.40%-14.49%+0.27%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+1.94%+8.01%+15.95%+10.90%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+7.27%-10.36%+6.18%-67.73%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+14.46%+36.86%+23.77%-26.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.705 of 5 stars
3.33.00.04.04.22.51.9
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8333 of 5 stars
2.35.04.23.93.61.71.9
Moderna, Inc. stock logo
MRNA
Moderna
4.3919 of 5 stars
4.02.00.04.61.92.50.6
Novavax, Inc. stock logo
NVAX
Novavax
4.6321 of 5 stars
3.12.00.04.73.30.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.63
Moderate Buy$595.9524.09% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.65
Moderate Buy$174.50-1.28% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5955.56% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.25
Hold$15.8665.52% Upside

Current Analyst Ratings Breakdown

Latest JNJ, ISRG, MRNA, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$547.00 ➝ $585.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$575.00 ➝ $595.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$590.00 ➝ $600.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$559.00 ➝ $599.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$605.00 ➝ $615.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B20.61$7.99 per share60.12$46.41 per share10.35
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$90.63B4.70$13.13 per share13.46$29.69 per share5.95
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.37N/AN/A$28.33 per share0.99
Novavax, Inc. stock logo
NVAX
Novavax
$1.08B1.44N/AN/A($3.89) per share-2.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$7.1766.9862.945.0328.51%14.56%12.93%10/16/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3518.9015.972.2525.00%32.49%13.00%10/21/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.284.20119.750.1139.20%-142.33%28.65%N/A

Latest JNJ, ISRG, MRNA, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.94%N/A55.61%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest JNJ, ISRG, MRNA, and NVAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.17
4.18
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34

Institutional Ownership

CompanyInstitutional Ownership
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.48 million355.97 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable

Recent News About These Companies

Novavax (NASDAQ:NVAX) Trading Down 5.7% - Here's Why
Novavax Stock Surges Amid Strategic Gains
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $15.86
TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)
Novavax (NASDAQ:NVAX) Shares Gap Up on Earnings Beat
Q2 2025 Novavax Inc Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$480.26 +3.18 (+0.67%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$478.96 -1.31 (-0.27%)
As of 06:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$176.76 +2.04 (+1.17%)
Closing price 08/15/2025 03:59 PM Eastern
Extended Trading
$176.82 +0.06 (+0.03%)
As of 06:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$28.02 +1.33 (+4.98%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$28.14 +0.12 (+0.43%)
As of 06:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$9.58 +0.15 (+1.59%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$9.85 +0.27 (+2.82%)
As of 06:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.